2017
Intracrine androgen biosynthesis in renal cell carcinoma
Lee G, Han C, Kwon Y, Patel R, Modi P, Kwon S, Faiena I, Patel N, Singer E, Ahn H, Kim W, Kim I. Intracrine androgen biosynthesis in renal cell carcinoma. British Journal Of Cancer 2017, 116: 937-943. PMID: 28253524, PMCID: PMC5379152, DOI: 10.1038/bjc.2017.42.Peer-Reviewed Original ResearchMeSH KeywordsAbiraterone AcetateAndrogensAnimalsAntineoplastic AgentsApoptosisBenzamidesBlotting, WesternCarcinoma, Renal CellCell ProliferationDihydrotestosteroneFemaleHumansImmunoenzyme TechniquesKidney NeoplasmsMaleMiceMice, NudeNitrilesOrchiectomyPhenylthiohydantoinPrognosisProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantReal-Time Polymerase Chain ReactionReceptors, AndrogenReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTestosteroneTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsRenal cell carcinomaCastration-resistant prostate cancerRCC cell linesAnti-androgen therapyHuman RCC cell linesAndrogen biosynthesisAbiraterone acetateCell carcinomaAndrogen receptorTumor volumeCell linesAndrogen deprivation therapyHigher tumor stageProstate cancer patientsMouse xenograft studiesGenitourinary cancersTumor suppressionSignificant tumor suppressionRCC patientsTumor stageCancer patientsMale miceProstate cancerIntratumoral steroidogenesisXenograft studies
2016
Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer
Parihar J, Kim I. Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer. 2016, 533-540. DOI: 10.1016/b978-0-12-800077-9.00057-8.Peer-Reviewed Original ResearchCastrate-resistant prostate cancerProstate cancerHormonal manipulationHormone-sensitive prostate cancerSecond-line hormonal manipulationsSecond-line hormonal therapySecond-line treatment optionAssociated response ratesInitial systemic therapySecondary hormonal manipulationsSecond-generation antiandrogensFirst-generation antiandrogensAntiandrogen withdrawalARN-509Hormonal therapyMainstay treatmentAbiraterone acetateAndrogen suppressionSystemic therapyAndrogen deprivationSuch patientsTreatment optionsTherapeutic responseDisease progressionResponse rate
2015
Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer
Han C, Patel R, Kim I. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Expert Opinion On Drug Metabolism & Toxicology 2015, 11: 967-975. PMID: 25936418, DOI: 10.1517/17425255.2015.1041918.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerMetastatic castration-resistant prostate cancerAbiraterone acetateMetastatic CRPCProstate cancerPhase III trialsBetter patient selectionHigh-level evidenceRisk of hypertensionDrug resistance patternsCurrent clinical challengesIntratumoral androgensOverall tolerabilityIII trialsPatient selectionClinical efficacySafety profileDevelopment of resistanceTreatment modalitiesDisease progressionTargeted therapyAndrogen sourceClinical challengeAndrogen signalingCYP 17